Should I buy or sell ClearPoint Neuro stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ClearPoint Neuro in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLPT shares. View CLPT analyst ratings or view top-rated stocks .

What is ClearPoint Neuro's stock price target for 2024?

3 equities research analysts have issued twelve-month target prices for ClearPoint Neuro's stock. Their CLPT share price targets range from $9.00 to $15.00. On average, they predict the company's share price to reach $12.00 in the next year. This suggests a possible upside of 122.6% from the stock's current price. View analysts price targets for CLPT or view top-rated stocks among Wall Street analysts .

How have CLPT shares performed in 2024?

ClearPoint Neuro's stock was trading at $6.79 at the beginning of 2024. Since then, CLPT shares have decreased by 20.6% and is now trading at $5.39. View the best growth stocks for 2024 here .

Are investors shorting ClearPoint Neuro?

ClearPoint Neuro saw a decrease in short interest in March. As of March 31st, there was short interest totaling 1,280,000 shares, a decrease of 8.6% from the March 15th total of 1,400,000 shares. Based on an average daily trading volume, of 152,300 shares, the days-to-cover ratio is presently 8.4 days. View ClearPoint Neuro's Short Interest .

When is ClearPoint Neuro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CLPT earnings forecast .

How were ClearPoint Neuro's earnings last quarter?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) posted its earnings results on Tuesday, March, 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.03. The firm had revenue of $6.81 million for the quarter, compared to the consensus estimate of $6.40 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 83.94% and a negative net margin of 92.21%.

What guidance has ClearPoint Neuro issued on next quarter's earnings?

ClearPoint Neuro issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $28.0 million-$32.0 million, compared to the consensus revenue estimate of $30.4 million.

How do I buy shares of ClearPoint Neuro?

Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CLPT

ClearPoint Neuro (CLPT) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free CLPT Stock Alerts

$5.39

-0.14 (-2.53%)

(As of 04/18/2024 ET)

Compare

Today's Range: $5.35
▼
$5.69
50-Day Range: $5.39
▼
$7.86
52-Week Range: $4.05
▼
$10.80

Volume: 86,697 shs
Average Volume: 149,083 shs
Market Capitalization: $145.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Get ClearPoint Neuro alerts:

ClearPoint Neuro MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 122.6% Upside
$12.00 Price Target
Short Interest: Healthy
4.73% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.95
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.75) to ($0.71) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.13 out of 5 stars

Medical Sector

539th out of 919 stocks

Surgical & Medical Instruments Industry

54th out of 93 stocks

3.5

Analyst's Opinion

Consensus Rating
ClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ClearPoint Neuro has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.73% of the outstanding shares of ClearPoint Neuro have been sold short.
Short Interest Ratio / Days to Cover
ClearPoint Neuro has a short interest ratio ("days to cover") of 8.4.
Change versus previous month
Short interest in ClearPoint Neuro has recently decreased by 8.57%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ClearPoint Neuro does not currently pay a dividend.
Dividend Growth
ClearPoint Neuro does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLPT.

2.8

News and Social Media Coverage

News Sentiment
ClearPoint Neuro has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for ClearPoint Neuro this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for CLPT on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.11% of the stock of ClearPoint Neuro is held by insiders.
Percentage Held by Institutions
Only 30.08% of the stock of ClearPoint Neuro is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.75) to ($0.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ClearPoint Neuro is -5.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ClearPoint Neuro is -5.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ClearPoint Neuro has a P/B Ratio of 6.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About ClearPoint Neuro Stock (NASDAQ:CLPT)

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

CLPT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLPT Stock News Headlines

April 16, 2024 | globenewswire.com

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

April 11, 2024 | investorplace.com

The 3 Most Promising MedTech Stocks to Invest In Now

April 18, 2024 | WealthPress (Ad)

Chances are you know the firms on this list

These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…

March 19, 2024 | globenewswire.com

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

March 16, 2024 | msn.com

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2023 Earnings Call Transcript

March 15, 2024 | finance.yahoo.com

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Annual Results: Here's What Analysts Are Forecasting For This Year

March 14, 2024 | finance.yahoo.com

ClearPoint Neuro Full Year 2023 Earnings: Beats Expectations

March 12, 2024 | finance.yahoo.com

ClearPoint Neuro Inc Reports Robust Revenue Growth in Q4 and Full-Year 2023

April 18, 2024 | WealthPress (Ad)

Chances are you know the firms on this list

March 12, 2024 | globenewswire.com

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results

March 11, 2024 | markets.businessinsider.com

ClearPoint Neuro is about to announce its earnings — here's what Wall Street expects

March 11, 2024 | benzinga.com

Earnings Outlook For ClearPoint Neuro

March 11, 2024 | finance.yahoo.com

Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System

March 7, 2024 | investorplace.com

The Top 7 Under-$15 Stocks to Buy in March 2024

March 1, 2024 | finance.yahoo.com

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

March 1, 2024 | globenewswire.com

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

February 29, 2024 | markets.businessinsider.com

ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

February 29, 2024 | globenewswire.com

ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

February 28, 2024 | globenewswire.com

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

February 22, 2024 | markets.businessinsider.com

ClearPoint Neuro’s Strategic Growth and Regulatory Milestones Bolster Buy Rating

February 21, 2024 | finance.yahoo.com

ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

February 18, 2024 | finance.yahoo.com

ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) largest shareholders are retail investors with 60% ownership, institutions own 32%

February 16, 2024 | finance.yahoo.com

ClearPoint Neuro, Inc. (CLPT)

February 15, 2024 | investorplace.com

The 3 Up-and-Coming Stocks That Could Make Your February Unforgettable

February 15, 2024 | investorplace.com

The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn't Ignore.

January 30, 2024 | msn.com

ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries

January 24, 2024 | finance.yahoo.com

ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo

See More Headlines

Receive CLPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:CLPT
CUSIP: N/A
CIK: 1285550
Web: www.clearpointneuro.com
Phone: (949) 900-6833
Fax: 949-900-6834
Employees: 107
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.00
High Stock Price Target: $15.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +110.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,090,000.00
Net Margins: -92.21%
Pretax Margin: -92.21%
Return on Equity: -83.94%
Return on Assets: -47.92%

Debt

Debt-to-Equity Ratio: 0.47
Current Ratio: 4.87
Quick Ratio: 3.80

Sales & Book Value

Annual Sales: $23.95 million
Price / Sales: 6.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.86 per share
Price / Book: 6.62

Miscellaneous

Outstanding Shares: 27,070,000
Free Float: 25,416,000
Market Cap: $154.03 million
Optionable: Optionable
Beta: 0.89

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Joseph Michael Burnett (Age 47)
President, CEO & Director
Comp: $803.12k
Mr. Danilo D'Alessandro (Age 38)
Chief Financial Officer
Comp: $459.26k
Mr. Jeremy Stigall (Age 40)
Chief Business Officer
Comp: $392.66k
Mr. Mazin Sabra (Age 43)
Chief Operating Officer
Ms. Ellisa Cholapranee
General Counsel & Secretary
Ms. Jacqueline Keller
Vice President of Marketing

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CLPT Stock Analysis - Frequently Asked Questions

Should I buy or sell ClearPoint Neuro stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ClearPoint Neuro in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLPT shares.
View CLPT analyst ratings or view top-rated stocks.
What is ClearPoint Neuro's stock price target for 2024?: 3 equities research analysts have issued twelve-month target prices for ClearPoint Neuro's stock. Their CLPT share price targets range from $9.00 to $15.00. On average, they predict the company's share price to reach $12.00 in the next year. This suggests a possible upside of 122.6% from the stock's current price.
View analysts price targets for CLPT or view top-rated stocks among Wall Street analysts.
How have CLPT shares performed in 2024?: ClearPoint Neuro's stock was trading at $6.79 at the beginning of 2024. Since then, CLPT shares have decreased by 20.6% and is now trading at $5.39.
View the best growth stocks for 2024 here.
Are investors shorting ClearPoint Neuro?: ClearPoint Neuro saw a decrease in short interest in March. As of March 31st, there was short interest totaling 1,280,000 shares, a decrease of 8.6% from the March 15th total of 1,400,000 shares. Based on an average daily trading volume, of 152,300 shares, the days-to-cover ratio is presently 8.4 days.
View ClearPoint Neuro's Short Interest.

When is ClearPoint Neuro's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CLPT earnings forecast.
How were ClearPoint Neuro's earnings last quarter?: ClearPoint Neuro, Inc. (NASDAQ:CLPT) posted its earnings results on Tuesday, March, 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.03. The firm had revenue of $6.81 million for the quarter, compared to the consensus estimate of $6.40 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 83.94% and a negative net margin of 92.21%.
What guidance has ClearPoint Neuro issued on next quarter's earnings?: ClearPoint Neuro issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $28.0 million-$32.0 million, compared to the consensus revenue estimate of $30.4 million.
How do I buy shares of ClearPoint Neuro?: Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLPT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial